# Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy

> **NCT06433050** · EARLY_PHASE1 · RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 26 (estimated)

## Conditions studied

- Hypertrophic Cardiomyopathy Without Obstruction

## Interventions

- **DRUG:** Sotagliflozin

## Key facts

- **NCT ID:** NCT06433050
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-17
- **Primary completion:** 2027-04
- **Final completion:** 2027-06
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06433050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06433050, "Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06433050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*